Paul obtained his PhD in Biochemistry working on protein phosphorylation and cell chuckle control with Carl Smythe and Philip Cohen at the MRC Protein Phosphorylation Unit in Dundee (1996)> He then moved to Boston to work on nuclear transport and signal transduction in yeast, working with Pamela Silver at the Dana-Farber Cancer Institute/Harvard Medical School.
On returning to the UK, he started Peptide Aptamer Groups at the MRC Cancer Cell Unit in Cambridge and at the Leeds Institute of Molecular Medicine. He founded Aptuscan Ltd in 2008 to enable broader access to the technologies he had been developing as an academic. Aptuscan was acquired by Avacta Group, plc in December 2011. Paul is now Chief Scientific Officer of Avacta Life Sciences, which is commercialising Affimers as alternatives to antibodies for life science R&D through its catalogue and custom Affimer discovery service. He is also a Visiting Member of the Astbury Centre for Structural and Molecular Biology and a Visiting Professor at Leeds University.